NSG 552: PSYCHOPHARMACOLOGY
COMPREHENSIVE EXAM BANK | 2026/2027 Edition | 250
Verified Questions
NSG 552 Psychopharmacology Exams 1, 2 & 3 - 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam bank for NSG 552 Psychopharmacology contains 250 verified practice
questions covering all major topics from Exams 1, 2, and 3. Each question is accompanied by a
detailed rationale and correct answer, ensuring a thorough review of psychopharmacological principles.
Designed for the 2026/2027 academic year, this resource reflects the latest evidence-based guidelines
and prepares students for success on the Wilkes University comprehensive exam.
Key Features:
Neurobiological basis of psychiatric disorders
Mechanisms of action for all major psychotropic drug classes
Clinical indications, side effects, and contraindications
Drug interactions and safety monitoring
Patient education and adherence strategies
Case-based application of psychopharmacology principles
Updates for 2026:
- Updated to reflect 2026/2027 DSM-5-TR and APA guidelines
- Revised rationales to incorporate latest FDA approvals and black-box warnings
- Added new questions on emerging therapies and pharmacogenomics
- Enhanced coverage of special populations (pregnancy, elderly, pediatric)
- Aligned with current Wilkes University NSG 552 curriculum objectives
Abstract:
This exam bank provides a rigorous and comprehensive review of psychopharmacology for graduate nursing
students. It integrates foundational neuroscience with clinical application, covering all major drug classes
including antidepressants, antipsychotics, mood stabilizers, anxiolytics, and stimulants. Each of the 250 questions
is crafted to test critical thinking and clinical reasoning, with detailed rationales explaining the correct answer and
distractor options. The content is organized by exam modules, allowing for targeted study and self-assessment.
Updated for the 2026/2027 academic year, this resource ensures alignment with current evidence-based practice
and prepares students for the Wilkes University comprehensive exam. It is an essential tool for achieving a high
score and demonstrating competency in psychopharmacology.
Keywords:
Psychopharmacology, NSG 552, Exam bank, Practice questions, Detailed rationales, Wilkes University, Nursing
advanced practice, 2026/2027
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining the underlying pharmacological principle, clinical reasoning, and why
the incorrect options are not appropriate. Rationales are evidence-based and reference current guidelines.
Compliance Checklist:
250 verified questions with accurate answers
Rationales updated to 2026/2027 evidence-based guidelines
Page 1
, Aligned with Wilkes University NSG 552 course objectives
Suitable for comprehensive exam preparation
Includes coverage of all major psychotropic drug classes
Designed for graduate-level nursing students
Content Area Overview:
Content Area Questions Key Topics Weight
Exam 1: Foundations & 1-60 Neurotransmission, receptor pharmacology, 24%
Neurobiology pharmacokinetics, pharmacodynamics,
neuroanatomy
Exam 2: Antidepressants & 61-130 SSRIs, SNRIs, TCAs, MAOIs, atypical 28%
Mood Stabilizers antidepressants, lithium, anticonvulsants
Exam 3: Antipsychotics, 131-200 Typical/atypical antipsychotics, 28%
Anxiolytics, & Stimulants benzodiazepines, buspirone, stimulants,
non-stimulant ADHD meds
Special Populations & Emerging 201-250 Pregnancy/lactation, pediatric, geriatric, 20%
Therapies pharmacogenomics, novel agents
Page 2
,Q1. A patient with schizophrenia has been stabilized on clozapine for 6 months. She
develops a fever, sore throat, and mouth ulcers. Which laboratory finding is most
concerning and requires immediate intervention?
A. White blood cell count of 3,000/µL
B. Absolute neutrophil count of 1,800/µL
C. Platelet count of 150,000/µL
D. Hemoglobin of 12.0 g/dL
Correct Answer: A. White blood cell count of 3,000/µL
Rationale: Clozapine can cause agranulocytosis, a potentially fatal drop in neutrophils.
An absolute neutrophil count (ANC) below 500/µL is critical, but a WBC count of 3,000/µL
is already concerning and requires immediate action per prescribing guidelines. The other
values are within or near normal limits and do not indicate agranulocytosis.
Why Wrong:
B - An ANC of 1,800/µL is slightly low but not critical; clozapine monitoring requires
more severe neutropenia to trigger intervention.
C - Platelet count of 150,000/µL is normal and not associated with clozapine-induced
agranulocytosis.
D - Hemoglobin of 12.0 g/dL is mildly low but not indicative of agranulocytosis.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5.
Q2. A patient on long-term lithium therapy presents with polyuria, polydipsia, and a
serum lithium level of 1.2 mEq/L. Which adverse effect is most likely, and what is the
best initial step?
A. Nephrogenic diabetes insipidus; obtain a 24-hour urine volume and consider
amiloride.
B. Diabetes mellitus; check blood glucose and start metformin.
C. Psychogenic polydipsia; restrict fluids and monitor lithium levels.
D. Syndrome of inappropriate antidiuretic hormone (SIADH); fluid restrict and
administer demeclocycline.
Correct Answer: A. Nephrogenic diabetes insipidus; obtain a 24-hour urine volume
and consider amiloride.
Rationale: Lithium can cause nephrogenic diabetes insipidus (NDI) by interfering with
aquaporin-2 channels. Polyuria and polydipsia are hallmark symptoms. Initial
management includes confirming the diagnosis with a 24-hour urine volume and
considering amiloride, which can reduce lithium-induced NDI. Diabetes mellitus and
SIADH are less likely given the presentation and lithium history.
Why Wrong:
B - Diabetes mellitus would present with hyperglycemia, not just polyuria and
polydipsia; lithium is not a common cause.
Page 3
, C - Psychogenic polydipsia is a diagnosis of exclusion and fluid restriction could
worsen lithium toxicity.
D - SIADH causes water retention and hyponatremia, not polyuria; demeclocycline is
for SIADH, not lithium-induced NDI.
Reference: Lehne, R. A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15.
Q3. Which of the following best explains the delayed therapeutic effect of SSRIs in
major depressive disorder?
A. The time required for monoamine oxidase inhibition to accumulate in the synaptic
cleft.
B. The need for downregulation of postsynaptic 5-HT1A receptors to enhance
serotonergic transmission.
C. The gradual desensitization of presynaptic 5-HT1A autoreceptors, leading to
increased serotonin release.
D. The time for the drug to cross the blood-brain barrier and reach steady-state
concentrations.
Correct Answer: C. The gradual desensitization of presynaptic 5-HT1A
autoreceptors, leading to increased serotonin release.
Rationale: SSRIs acutely increase synaptic serotonin, but the therapeutic effect requires
weeks because the initial increase activates somatodendritic 5-HT1A autoreceptors, which
reduce firing. Over time, these autoreceptors desensitize, allowing enhanced serotonergic
neurotransmission. This accounts for the delayed onset. Monoamine oxidase inhibition is
not relevant to SSRIs, and downregulation of postsynaptic receptors would reduce, not
enhance, transmission.
Why Wrong:
A - SSRIs do not inhibit monoamine oxidase; that is the mechanism of MAOIs.
B - Downregulation of postsynaptic 5-HT1A receptors is not a primary mechanism; it
is the presynaptic autoreceptors that matter.
D - SSRIs cross the blood-brain barrier and reach steady state within days, but
therapeutic effects still take weeks.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6.
Q4. A patient with bipolar disorder is stabilized on valproate. She becomes pregnant.
Which statement is most accurate regarding the risks of valproate use during
pregnancy?
A. Valproate is safe in pregnancy; the benefits outweigh the risks for seizure control.
B. Valproate is associated with neural tube defects and cognitive impairment in the
child; it should be avoided if possible.
C. Valproate is contraindicated only in the first trimester; it is safe later in pregnancy.
Page 4
COMPREHENSIVE EXAM BANK | 2026/2027 Edition | 250
Verified Questions
NSG 552 Psychopharmacology Exams 1, 2 & 3 - 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam bank for NSG 552 Psychopharmacology contains 250 verified practice
questions covering all major topics from Exams 1, 2, and 3. Each question is accompanied by a
detailed rationale and correct answer, ensuring a thorough review of psychopharmacological principles.
Designed for the 2026/2027 academic year, this resource reflects the latest evidence-based guidelines
and prepares students for success on the Wilkes University comprehensive exam.
Key Features:
Neurobiological basis of psychiatric disorders
Mechanisms of action for all major psychotropic drug classes
Clinical indications, side effects, and contraindications
Drug interactions and safety monitoring
Patient education and adherence strategies
Case-based application of psychopharmacology principles
Updates for 2026:
- Updated to reflect 2026/2027 DSM-5-TR and APA guidelines
- Revised rationales to incorporate latest FDA approvals and black-box warnings
- Added new questions on emerging therapies and pharmacogenomics
- Enhanced coverage of special populations (pregnancy, elderly, pediatric)
- Aligned with current Wilkes University NSG 552 curriculum objectives
Abstract:
This exam bank provides a rigorous and comprehensive review of psychopharmacology for graduate nursing
students. It integrates foundational neuroscience with clinical application, covering all major drug classes
including antidepressants, antipsychotics, mood stabilizers, anxiolytics, and stimulants. Each of the 250 questions
is crafted to test critical thinking and clinical reasoning, with detailed rationales explaining the correct answer and
distractor options. The content is organized by exam modules, allowing for targeted study and self-assessment.
Updated for the 2026/2027 academic year, this resource ensures alignment with current evidence-based practice
and prepares students for the Wilkes University comprehensive exam. It is an essential tool for achieving a high
score and demonstrating competency in psychopharmacology.
Keywords:
Psychopharmacology, NSG 552, Exam bank, Practice questions, Detailed rationales, Wilkes University, Nursing
advanced practice, 2026/2027
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is clearly indicated,
followed by a detailed rationale explaining the underlying pharmacological principle, clinical reasoning, and why
the incorrect options are not appropriate. Rationales are evidence-based and reference current guidelines.
Compliance Checklist:
250 verified questions with accurate answers
Rationales updated to 2026/2027 evidence-based guidelines
Page 1
, Aligned with Wilkes University NSG 552 course objectives
Suitable for comprehensive exam preparation
Includes coverage of all major psychotropic drug classes
Designed for graduate-level nursing students
Content Area Overview:
Content Area Questions Key Topics Weight
Exam 1: Foundations & 1-60 Neurotransmission, receptor pharmacology, 24%
Neurobiology pharmacokinetics, pharmacodynamics,
neuroanatomy
Exam 2: Antidepressants & 61-130 SSRIs, SNRIs, TCAs, MAOIs, atypical 28%
Mood Stabilizers antidepressants, lithium, anticonvulsants
Exam 3: Antipsychotics, 131-200 Typical/atypical antipsychotics, 28%
Anxiolytics, & Stimulants benzodiazepines, buspirone, stimulants,
non-stimulant ADHD meds
Special Populations & Emerging 201-250 Pregnancy/lactation, pediatric, geriatric, 20%
Therapies pharmacogenomics, novel agents
Page 2
,Q1. A patient with schizophrenia has been stabilized on clozapine for 6 months. She
develops a fever, sore throat, and mouth ulcers. Which laboratory finding is most
concerning and requires immediate intervention?
A. White blood cell count of 3,000/µL
B. Absolute neutrophil count of 1,800/µL
C. Platelet count of 150,000/µL
D. Hemoglobin of 12.0 g/dL
Correct Answer: A. White blood cell count of 3,000/µL
Rationale: Clozapine can cause agranulocytosis, a potentially fatal drop in neutrophils.
An absolute neutrophil count (ANC) below 500/µL is critical, but a WBC count of 3,000/µL
is already concerning and requires immediate action per prescribing guidelines. The other
values are within or near normal limits and do not indicate agranulocytosis.
Why Wrong:
B - An ANC of 1,800/µL is slightly low but not critical; clozapine monitoring requires
more severe neutropenia to trigger intervention.
C - Platelet count of 150,000/µL is normal and not associated with clozapine-induced
agranulocytosis.
D - Hemoglobin of 12.0 g/dL is mildly low but not indicative of agranulocytosis.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 5.
Q2. A patient on long-term lithium therapy presents with polyuria, polydipsia, and a
serum lithium level of 1.2 mEq/L. Which adverse effect is most likely, and what is the
best initial step?
A. Nephrogenic diabetes insipidus; obtain a 24-hour urine volume and consider
amiloride.
B. Diabetes mellitus; check blood glucose and start metformin.
C. Psychogenic polydipsia; restrict fluids and monitor lithium levels.
D. Syndrome of inappropriate antidiuretic hormone (SIADH); fluid restrict and
administer demeclocycline.
Correct Answer: A. Nephrogenic diabetes insipidus; obtain a 24-hour urine volume
and consider amiloride.
Rationale: Lithium can cause nephrogenic diabetes insipidus (NDI) by interfering with
aquaporin-2 channels. Polyuria and polydipsia are hallmark symptoms. Initial
management includes confirming the diagnosis with a 24-hour urine volume and
considering amiloride, which can reduce lithium-induced NDI. Diabetes mellitus and
SIADH are less likely given the presentation and lithium history.
Why Wrong:
B - Diabetes mellitus would present with hyperglycemia, not just polyuria and
polydipsia; lithium is not a common cause.
Page 3
, C - Psychogenic polydipsia is a diagnosis of exclusion and fluid restriction could
worsen lithium toxicity.
D - SIADH causes water retention and hyponatremia, not polyuria; demeclocycline is
for SIADH, not lithium-induced NDI.
Reference: Lehne, R. A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 15.
Q3. Which of the following best explains the delayed therapeutic effect of SSRIs in
major depressive disorder?
A. The time required for monoamine oxidase inhibition to accumulate in the synaptic
cleft.
B. The need for downregulation of postsynaptic 5-HT1A receptors to enhance
serotonergic transmission.
C. The gradual desensitization of presynaptic 5-HT1A autoreceptors, leading to
increased serotonin release.
D. The time for the drug to cross the blood-brain barrier and reach steady-state
concentrations.
Correct Answer: C. The gradual desensitization of presynaptic 5-HT1A
autoreceptors, leading to increased serotonin release.
Rationale: SSRIs acutely increase synaptic serotonin, but the therapeutic effect requires
weeks because the initial increase activates somatodendritic 5-HT1A autoreceptors, which
reduce firing. Over time, these autoreceptors desensitize, allowing enhanced serotonergic
neurotransmission. This accounts for the delayed onset. Monoamine oxidase inhibition is
not relevant to SSRIs, and downregulation of postsynaptic receptors would reduce, not
enhance, transmission.
Why Wrong:
A - SSRIs do not inhibit monoamine oxidase; that is the mechanism of MAOIs.
B - Downregulation of postsynaptic 5-HT1A receptors is not a primary mechanism; it
is the presynaptic autoreceptors that matter.
D - SSRIs cross the blood-brain barrier and reach steady state within days, but
therapeutic effects still take weeks.
Reference: Stahl, S. M. (2021). Stahl's Essential Psychopharmacology, 5th Ed., Ch. 6.
Q4. A patient with bipolar disorder is stabilized on valproate. She becomes pregnant.
Which statement is most accurate regarding the risks of valproate use during
pregnancy?
A. Valproate is safe in pregnancy; the benefits outweigh the risks for seizure control.
B. Valproate is associated with neural tube defects and cognitive impairment in the
child; it should be avoided if possible.
C. Valproate is contraindicated only in the first trimester; it is safe later in pregnancy.
Page 4
